AzTrials
AzTrials

TinnitusTIDENCT06520865

TIDE Project: Biomarker Discovery for Chronic Tinnitus Diagnosis

An observational study of Tinnitus, run by University of Regensburg at 7 sites in 5 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Research in clinical neuroscience is founded on the conviction that a better understanding of tinnitus related changes of brain function will improve our ability to diagnose and treat tinnitus. Read more about this study

Who is it for?
Ages 18 to 70 yearsHealthy volunteers can take part
Conditions the study is for
Tinnitus
What is being tested?
Acoustic paradigms
How many people
560 participants
Where
7 sitesin 5 countries
Study dates
1 Aug 2024to 30 Nov 2025
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Patients who have been diagnosed with chronic tinnitus (for at least 6 months) and control subjects who have never had (except short-term) tinnitus.

Who may be able to join

  • for tinnitus cases: a diagnosis of chronic and constant tinnitus (for at least 6 months based on history)
  • (2) for controls: never experienced tinnitus
  • (3) age 18 -70;
  • (4) ability to understand and consent to the research;
  • (5) ability to participate (hearing ability);
  • (6) MoCa Test ≥ 26;
  • (7) hyperacusis questionnaire score < 27;

Who cannot join

  • (1) objective tinnitus; heartbeat-synchronous tinnitus as primary complaint;
  • (2) otosclerosis; acoustic neuroma or other relevant ear disorders with fluctuating hearing;
  • (3) acute ear nose and throat infections (acute otitis media, otitis externa, acute sinusitis);
  • (4) Meniere's disease or similar syndromes;
  • (5) vestibular migraine;
  • (6) serious internal, neurological or psychiatric conditions;
Show all 12Show fewer
  • (7) epilepsy or other CNS disorders (brain tumor, encephalitis);
  • (8) clinically relevant drug, medication or alcohol abuse up to 12 weeks before study start;
  • (9) change in anti-depressants/drugs ≤ 2 weeks
  • (10) missing written informed consent
  • (11) severe hearing loss - inability to communicate properly in the course of the study;
  • (12) one deaf ear;

Trial locations and contacts

7 sites in 5 countries.

7 sites in 5 countries

United States2 sites
  • University of Texas

    Austin, Texas, 78712

  • University of Illinois

    Champaign, Illinois, 61820

Other trials in United States

Germany2 sites
  • Center of Neuromodulation - Psychiatry und Psychotherapie der Universität Regensburg am Bezirksklinikum

    Regensburg, Bavaria, 93053

  • University of Tuebingen

    Tübingen, Baden-Wurttemberg, 72074

Other trials in Germany

Belgium1 site
  • Brai3n - Research center for Advanced, International, Innovative and Interdisciplinary Neuromodulation

    Ghent, 9000

Other trials in Belgium

Ireland1 site
  • Trinity College Dublin

    Dublin

Other trials in Ireland

Switzerland1 site
  • OST - Eastern Switzerland University of Applied Sciences

    Sankt Gallen, 9000

Other trials in Switzerland

About this study

Official title: Identification and Validation of a Biomarker for Tinnitus: an Objective Data-driven Personalized Approach to Diagnosis of Chronic Tinnitus - The Tinnitus Detection (TIDE) Project

Research in clinical neuroscience is founded on the conviction that a better understanding of tinnitus related changes of brain function will improve our ability to diagnose and treat tinnitus. Although considerable advances have been made in understanding the mechanisms of tinnitus, the clinical management of tinnitus remains largely based on a 'trial and error' approach. The identification and validation of a biomarker for tinnitus is thought to be the crucial step in the development of a personalized approach to the diagnosis and treatment of tinnitus. The overarching goal of this study is to incorporate advanced technologies to provide an objective, data-driven, personalized approach to the diagnosis of chronic tinnitus. This should lead to a clinically applicable tool that can be widely and easily used.

Read the detailed description

The tinnitus detect (TIDE) consortium has been designed to identify and validate a biomarker for the presence and intensity of tinnitus. For this purpose, two test paradigms are combined which are derived from the most recent models of tinnitus and which have shown promise in pilot studies.

A first approach is based on a method used in animals to objectively assess tinnitus by gap detection, namely Gap prepulse inhibition of the acoustic startle (GPIAS). The GPIAS paradigm is inspired from the combination of both gap detection and pre-pulse inhibition (PPI), used for the assessment of temporal sensory processing in both animals and humans. The basic principle of PPI relies on the ability of a weak lead stimulus (a prepulse or a silent gap presented in a carrier background) to inhibit a startling effect of a following, more intense, abrupt stimulus. These paradigms have been used to assess the automatic or preconscious inhibition of the motor reflex response that occurs in healthy subjects. Because GPIAS is regulated at the level of the auditory cortex, cortical responses may provide a more accurate measure of inhibition than motor reflex responses, such as the startle response in animals or the eye blinking in humans. The hypothesis is that individuals with tinnitus would have impaired inhibition of cortical evoked responses to sound pulses when preceded by a silent gap, in comparison to non-tinnitus individuals, due to the ongoing tinnitus percept.

A second approach is based on the concept that tinnitus occurrence is related to altered processing of prediction errors. This concept is supported by empirical evidence demonstrating that people with tinnitus exhibit a more pronounced electrophysiological response to a mismatch between predictions (the expected sound based on the auditory training paradigm) and perceptions as compared to non-tinnitus individuals. This sensitivity to prediction errors (the difference between prediction and input) is associated with how loud patients perceive their tinnitus, independent of co-occurring hyperacusis and hearing loss. For example, the amplitude of the mismatch negativity (MMN) positively correlates with subjectively reported tinnitus loudness. Thus, the MMN might be a biomarker for how loud tinnitus patients perceive their tinnitus. That is, people with a more pronounced electrophysiological response to a prediction error perceive a louder phantom sound. Using another paradigm, a group, independent of us, confirmed the importance of the MMN for tinnitus detection. Furthermore, an increase in amplitude and a delay in latency for the late positive evoked brain response (P300) has been demonstrated in tinnitus patients using both auditory and visual oddball paradigms. Both the MMN and P300 are conceived as measures of prediction errors identified at respectively the sensory cortex and higher levels (i.e., frontal-parietal cortex). The P300 is thought to reflect processes involved in stimulus evaluation or categorization; whether the stimulus is behaviourally relevant or not. Therefore, the aim of the current approach is to validate that both the MMN and the P300, using an auditory oddball paradigm with omission, can be used as biomarkers for tinnitus loudness and presence, respectively, (i.e., cross-validation).

We propose to investigate these two paradigms in a large international sample of tinnitus patients and controls in order to determine the sensitivity of GPIAS and the oddball paradigm in diagnosing tinnitus in humans.

Conditions
Tinnitus
Being tested
Acoustic paradigms
Keywords
Tinnitus, Biomarker for Tinnitus
Medical subject headings
Tinnitus

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Acoustic paradigmsOther

    Acoustic oddball Gap detection

Study groups in NCT06520865
Study groupRoleWhat they receive
Tinnitus cases/patientsSubjects that have a diagnosis of chronic and constant tinnitus (for at least 6 months based on history)
Receives: Other: Acoustic paradigms
Control groupSubjects that never experienced tinnitus (excluding short-term tinnitus, i.e. not tinnitus that persists over a longer period of time)
Receives: Other: Acoustic paradigms

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Event-related potentials

    Event-related potentials of a 64-channel EEG

    Measured: 4 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Jul 2024
  2. Study start1 Aug 2024
  3. Primary completion30 Nov 2025
  4. Study completion30 Nov 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
560 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06520865
Sponsor's protocol ID
TIDE
Acronym
TIDE
Status last verified
Dec 2025
First submitted
22 Jul 2024
Last updated
24 Mar 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Vanneste S, Yasoda-Mohan A, Chen F, Arulchelvan E, Shields N, Braun C, Campbell J, De Ridder D, Engelke M, Fink S, Husain FT, Jain N, Kleinjung T, Kim G, Knipper M, Langguth B, Lu H, Neff P, Ralston L, Riegger E, Ruttiger L, Schlee W, Todtli B, Shabestari PS, Ajmera S, Staudinger S, Wolpert S, Cederroth CR. Objective data-driven personalised approach to diagnosis of chronic tinnitus: the Tinnitus Detection (TIDE) project - protocol for the identification and validation of a biomarker for tinnitus. BMJ Open. 2026 May 19;16(5):e112788. doi: 10.1136/bmjopen-2025-112788.

    PubMed 42156141

Questions about this trial

What is this clinical trial studying?

An observational study of Tinnitus, run by University of Regensburg at 7 sites in 5 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 24 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 7 sites in United States, Germany, Belgium, Ireland, Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Event-related potentials (time frame: 4 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06520865, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Mar 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in